A Real-World Experience of Rituximab: A Panacea in Therapy of Multiple Sclerosis in Low- and Middle-Income Setting.
Pritam RajaKamakshi DhamijaSamim MmKulanthaivelu KarthikMandara Ganganakudige ManjappaiahThennarasu KandavelNetravathi MPublished in: Clinical neuropharmacology (2024)
Rituximab is a safe, well-tolerated, easily accessible, inexpensive, and effective therapeutic option for people with MS. Rituximab showed both clinical and radiological improvement after a median follow-up of 1.5 years. None of our patients showed any severe COVID infection nor side effects after receiving COVID vaccination.
Keyphrases
- multiple sclerosis
- diffuse large b cell lymphoma
- end stage renal disease
- chronic lymphocytic leukemia
- ejection fraction
- hodgkin lymphoma
- sars cov
- coronavirus disease
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- mental health
- ms ms
- stem cells
- patient reported outcomes
- drug induced
- mesenchymal stem cells
- respiratory syndrome coronavirus